Morris D. Groves

8.6k total citations · 2 hit papers
109 papers, 4.9k citations indexed

About

Morris D. Groves is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Morris D. Groves has authored 109 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Genetics, 58 papers in Pulmonary and Respiratory Medicine and 53 papers in Oncology. Recurrent topics in Morris D. Groves's work include Glioma Diagnosis and Treatment (70 papers), Brain Metastases and Treatment (53 papers) and Lung Cancer Research Studies (17 papers). Morris D. Groves is often cited by papers focused on Glioma Diagnosis and Treatment (70 papers), Brain Metastases and Treatment (53 papers) and Lung Cancer Research Studies (17 papers). Morris D. Groves collaborates with scholars based in United States, Netherlands and Switzerland. Morris D. Groves's co-authors include Kenneth R. Hess, Patrick Y. Wen, Vinay K. Puduvalli, Victor A. Levin, W.K. Alfred Yung, Mark R. Gilbert, Marc C. Chamberlain, Jeffrey S. Weinberg, Michael Glantz and Michael D. Wetzel and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.

In The Last Decade

Morris D. Groves

104 papers receiving 4.8k citations

Hit Papers

The Identification and Characterization of Breast Cancer ... 2013 2026 2017 2021 2013 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis
    2013 412 citations Lixin Zhang, Lon D. Ridgway et al. Science Translational Medicine profile →
  2. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
    2015 313 citations David A. Reardon, Morris D. Groves et al. Neuro-Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Morris D. Groves United States 42 2.5k 2.1k 2.1k 1.4k 1000 109 4.9k
David M. Peereboom United States 39 2.2k 0.9× 1.7k 0.8× 1.7k 0.8× 1.3k 0.9× 613 0.6× 198 4.8k
Nina A. Paleologos United States 25 3.4k 1.4× 2.3k 1.1× 1.5k 0.7× 852 0.6× 704 0.7× 49 5.0k
Yoshitaka Narita Japan 37 2.6k 1.0× 1.2k 0.6× 1.3k 0.6× 2.0k 1.4× 1.2k 1.2× 234 5.6k
M. Kelly Nicholas United States 26 2.8k 1.1× 1.2k 0.6× 863 0.4× 1.6k 1.1× 1.1k 1.1× 64 4.5k
Enrico Franceschi Italy 38 4.1k 1.6× 2.0k 0.9× 1.2k 0.6× 1.4k 1.0× 1.1k 1.1× 193 5.8k
Alicia Tosoni Italy 29 2.9k 1.2× 1.3k 0.6× 771 0.4× 1.1k 0.8× 842 0.8× 103 4.2k
Priscilla K. Brastianos United States 39 1.9k 0.8× 2.4k 1.1× 1.9k 0.9× 1.1k 0.8× 594 0.6× 175 5.4k
Christine Fuller United States 37 2.5k 1.0× 1.1k 0.5× 2.1k 1.0× 3.7k 2.6× 1.3k 1.3× 120 6.8k
Jörg C. Tonn Germany 38 2.9k 1.2× 925 0.4× 736 0.4× 1.9k 1.4× 1.3k 1.3× 59 5.3k
Jeffrey J. Raizer United States 43 3.3k 1.3× 2.0k 0.9× 1.5k 0.7× 1.4k 1.0× 750 0.8× 175 6.2k

Countries citing papers authored by Morris D. Groves

Since Specialization
Citations

This map shows the geographic impact of Morris D. Groves's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Morris D. Groves with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Morris D. Groves more than expected).

Fields of papers citing papers by Morris D. Groves

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Morris D. Groves. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Morris D. Groves. The network helps show where Morris D. Groves may publish in the future.

Co-authorship network of co-authors of Morris D. Groves

This figure shows the co-authorship network connecting the top 25 collaborators of Morris D. Groves. A scholar is included among the top collaborators of Morris D. Groves based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Morris D. Groves. Morris D. Groves is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Khasraw, Mustafa, Michael Weller, David Lorente, et al.. (2021). Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances. 3(1). vdab058–vdab058. 18 indexed citations
3.
Malani, Rachna, Martin Fleisher, Priya Kumthekar, et al.. (2020). Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal of Neuro-Oncology. 148(3). 599–606. 62 indexed citations
4.
Boire, Adrienne, Dieta Brandsma, Priscilla K. Brastianos, et al.. (2019). Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro-Oncology. 21(5). 571–584. 107 indexed citations
5.
6.
Reardon, David A., Morris D. Groves, Patrick Y. Wen, et al.. (2013). A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. Clinical Cancer Research. 19(4). 900–908. 91 indexed citations
7.
Zhang, Lixin, Lon D. Ridgway, Michael D. Wetzel, et al.. (2013). The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis. Science Translational Medicine. 5(180). 180ra48–180ra48. 412 indexed citations breakdown →
8.
Yust‐Katz, Shlomit, D. Liu, Yuan Yuan, et al.. (2013). Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. Journal of Neuro-Oncology. 114(2). 229–235. 42 indexed citations
9.
Yust‐Katz, Shlomit, et al.. (2013). Leptomeningeal metastases from genitourinary cancer: The University of Texas MD Anderson Cancer Center experience. Medical Oncology. 30(1). 429–429. 39 indexed citations
10.
Walker, Julie, et al.. (2012). Intraventricular Topotecan for the Treatment of Neoplastic Meningitis: Five Case Studies. Journal of the Advanced Practitioner in Oncology. 3(4). 237–41. 1 indexed citations
11.
Groves, Morris D., et al.. (2012). Helping Patients Make the Best Decision Regarding Duration of Temozolomide Chemotherapy Treatment. CONTINUUM Lifelong Learning in Neurology. 18(2). 421–425. 4 indexed citations
12.
Giglio, Pierre, Kenneth R. Hess, Mark R. Gilbert, et al.. (2011). Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 118(14). 3599–3606. 12 indexed citations
13.
Gehring, Karin, Robert G. Collins, Morris D. Groves, et al.. (2011). A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. Journal of Neuro-Oncology. 107(1). 165–174. 109 indexed citations
14.
Groves, Morris D.. (2010). New Strategies in the Management of Leptomeningeal Metastases. Archives of Neurology. 67(3). 305–12. 62 indexed citations
15.
Rivera, Edgardo, Christina Meyers, Morris D. Groves, et al.. (2006). Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 107(6). 1348–1354. 119 indexed citations
16.
Colman, Howard, Brian Berkey, Moshe Maor, et al.. (2006). Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-β for supratentorial glioblastoma: Results of RTOG 9710. International Journal of Radiation Oncology*Biology*Physics. 66(3). 818–824. 45 indexed citations
17.
Groves, Morris D., Vinay K. Puduvalli, Charles A. Conrad, et al.. (2006). Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status. Journal of Neuro-Oncology. 80(1). 83–90. 41 indexed citations
18.
Levin, Victor A., Pierre Giglio, Vinay K. Puduvalli, et al.. (2005). Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. Journal of Neuro-Oncology. 78(1). 85–90. 35 indexed citations
19.
McDonald, J. Matthew, Siew Ju See, Mark R. Gilbert, et al.. (2005). The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 104(7). 1468–1477. 86 indexed citations
20.
Groves, Morris D.. (2003). The pathogenesis of neoplastic meningitis. Current Oncology Reports. 5(1). 15–23. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David M. Peereboom Breakdown of academic impact, for papers by Nina A. Paleologos Breakdown of academic impact, for papers by Yoshitaka Narita Breakdown of academic impact, for papers by M. Kelly Nicholas Breakdown of academic impact, for papers by Enrico Franceschi Breakdown of academic impact, for papers by Alicia Tosoni Breakdown of academic impact, for papers by Priscilla K. Brastianos Breakdown of academic impact, for papers by Christine Fuller Breakdown of academic impact, for papers by Jörg C. Tonn Breakdown of academic impact, for papers by Jeffrey J. Raizer
Rankless by CCL
2026